These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39176265)

  • 1. A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: an exploratory study.
    Zhong W; Yan L; Zhu Y; Shi L; He Y; Chen T; Zheng J
    Front Cell Infect Microbiol; 2024; 14():1426960. PubMed ID: 39176265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
    Wen C; Wang Y; Tian H; Lei Y; Wang Z; Cai D; Zhou Z; Shi X
    Front Cell Infect Microbiol; 2023; 13():1332232. PubMed ID: 38292859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of short-term Peg-IFN α-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study.
    Li Y; Yang S; Li C; Ma Z; Zhang M; Zou W; Wu Z; Hou H; Wang W; Zhu L
    Virol J; 2024 Sep; 21(1):231. PubMed ID: 39334422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B.
    Wang J; Zhang Z; Zhu L; Zhang Q; Zhang S; Pan Y; Liu J; Cao F; Fan T; Xiong Y; Yin S; Yan X; Chen Y; Zhu C; Li J; Liu X; Wu C; Huang R
    Virulence; 2024 Dec; 15(1):2404965. PubMed ID: 39317345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H; Yang RF; Wei L
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].
    Hou FQ; Yin YL; Zeng LY; Shang J; Gong GZ; Pan C; Zhang MX; Yin CB; Xie Q; Peng YZ; Chen SJ; Mao Q; Chen YP; Mao QG; Zhang DZ; Han T; Wang MR; Zhao W; Liu JJ; Han Y; Zhao LF; Luo GH; Zhang JM; Peng J; Tan DM; Li ZW; Tang H; Wang H; Zhang YX; Li J; Zhang LL; Chen L; Jia JD; Chen CW; Zhen Z; Li BS; Niu JQ; Meng QH; Yuan H; Sun YT; Li SC; Sheng JF; Cheng J; Sun L; Wang GQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):589-596. PubMed ID: 29056008
    [No Abstract]   [Full Text] [Related]  

  • 13. Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: a case series study.
    Zeng QL; Chen RY; Lv XY; Huang S; Li WZ; Pan YJ; Wang FS; Yu ZJ
    BMC Infect Dis; 2024 Aug; 24(1):830. PubMed ID: 39148030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
    J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
    Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
    World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
    Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
    [No Abstract]   [Full Text] [Related]  

  • 19. Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy.
    Luo H; Tan G; Hu X; Li Y; Lei D; Zeng Y; Qin B
    Virol J; 2023 Jul; 20(1):161. PubMed ID: 37475028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
    Buster EH; Flink HJ; Simsek H; Heathcote EJ; Sharmila S; Kitis GE; Gerken G; Buti M; de Vries RA; Verhey E; Hansen BE; Janssen HL
    Am J Gastroenterol; 2009 Oct; 104(10):2449-57. PubMed ID: 19584831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.